Jul 19, 2022 9:15 am EDT Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy
Jun 27, 2022 7:00 am EDT Capricor Therapeutics Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with CAP-1002 in HOPE-2 Open Label Extension Study
Jun 17, 2022 9:00 am EDT Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual Conference
May 18, 2022 9:00 am EDT Capricor Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 10, 2022 4:01 pm EDT Capricor Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 03, 2022 8:30 am EDT Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10
Mar 29, 2022 9:00 am EDT Capricor Therapeutics to Participate in the Cantor Fitzgerald Rare Orphan Disease Summit
Mar 28, 2022 8:30 am EDT Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory INSPIRE Trial in Severe Hospitalized COVID-19 Patients
Mar 11, 2022 8:00 am EST The Lancet Publishes Positive Results from Capricor Therapeutics’ Phase 2 Study Evaluating CAP-1002 in Late-Stage Duchenne Muscular Dystrophy